Cargando…

Gaining Mechanistic Insight Into Coproporphyrin I as Endogenous Biomarker for OATP1B‐Mediated Drug–Drug Interactions Using Population Pharmacokinetic Modeling and Simulation

This study evaluated coproporphyrin I (CPI) as a selective endogenous biomarker of OATP1B‐mediated drug–drug interactions (DDIs) relative to clinical probe rosuvastatin using nonlinear mixed‐effect modeling. Plasma and urine CPI data in the presence/absence of rifampicin were modeled to describe CPI...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barnett, Shelby, Ogungbenro, Kayode, Ménochet, Karelle, Shen, Hong, Lai, Yurong, Humphreys, W. Griffith, Galetin, Aleksandra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6175062/ https://www.ncbi.nlm.nih.gov/pubmed/29243231 http://dx.doi.org/10.1002/cpt.983

Ejemplares similares

PBPK Model of Coproporphyrin I: Evaluation of the Impact of SLCO1B1 Genotype, Ethnicity, and Sex on its Inter‐Individual Variability
por: Takita, Hiroyuki, et al.
Publicado: (2021)

Coproporphyrin I as an Endogenous Biomarker to Detect Reduced OATP1B Activity and Shift in Elimination Route in Chronic Kidney Disease
por: Takita, Hiroyuki, et al.
Publicado: (2022)

Physiologically‐based pharmacokinetic model‐based translation of OATP1B‐mediated drug–drug interactions from coproporphyrin I to probe drugs
por: Mochizuki, Tatsuki, et al.
Publicado: (2022)

PBPK Modeling of Coproporphyrin I as an Endogenous Biomarker for Drug Interactions Involving Inhibition of Hepatic OATP1B1 and OATP1B3
por: Yoshikado, Takashi, et al.
Publicado: (2018)

Estimation of FMO3 Ontogeny by Mechanistic Population Pharmacokinetic Modelling of Risdiplam and Its Impact on Drug–Drug Interactions in Children
por: Cleary, Yumi, et al.
Publicado: (2023)

Quantification of OATP1B1 endogenous metabolites coproporphyrin I and III in human urine
por: Jang, Yeonseo, et al.
Publicado: (2023)

Relationship of hemoglobin level and plasma coproporphyrin‐I concentrations as an endogenous probe for phenotyping OATP1B
por: Suzuki, Yosuke, et al.
Publicado: (2021)

Population pharmacokinetic modeling and simulation to support qualification of pyridoxic acid as endogenous biomarker of OAT1/3 renal transporters
por: Ahmad, Amais, et al.
Publicado: (2021)

Performance of Plasma Coproporphyrin I and III as OATP1B1 Biomarkers in Humans
por: Neuvonen, Mikko, et al.
Publicado: (2021)

Coproporphyrin I Can Serve as an Endogenous Biomarker for OATP1B1 Inhibition: Assessment Using a Glecaprevir/Pibrentasvir Clinical Study
por: Kalluri, Hari V., et al.
Publicado: (2020)

A population pharmacokinetic model for simvastatin and its metabolites in children and adolescents
por: Ogungbenro, Kayode, et al.
Publicado: (2019)

Model‐Based Drug–Drug Interaction Extrapolation Strategy From Adults to Children: Risdiplam in Pediatric Patients With Spinal Muscular Atrophy
por: Cleary, Yumi, et al.
Publicado: (2021)

Physiologically‐based pharmacokinetic modeling for investigating the effect of simeprevir on concomitant drugs and an endogenous biomarker of OATP1B
por: Nakayama, Shinji, et al.
Publicado: (2023)

Substantially Increased Plasma Coproporphyrin‐I Concentrations Associated With OATP1B1*15 Allele in Japanese General Population
por: Suzuki, Yosuke, et al.
Publicado: (2020)

Physiologically Based Pharmacokinetic Modeling of Transporter-Mediated Hepatic Disposition of Imaging Biomarker Gadoxetate in Rats
por: Scotcher, Daniel, et al.
Publicado: (2021)

Use of Physiologically Based Pharmacokinetic Modeling to Evaluate the Effect of Chronic Kidney Disease on the Disposition of Hepatic CYP2C8 and OATP1B Drug Substrates
por: Tan, Ming‐Liang, et al.
Publicado: (2018)

Quantitative Prediction of OATP‐Mediated Drug‐Drug Interactions With Model‐Based Analysis of Endogenous Biomarker Kinetics
por: Yoshida, Kenta, et al.
Publicado: (2018)

The coproporphyrin ferrochelatase of Staphylococcus aureus: mechanistic insights into a regulatory iron-binding site
por: Hobbs, Charlie, et al.
Publicado: (2017)

Cluster Gauss‐Newton method analyses of PBPK model parameter combinations of coproporphyrin‐I based on OATP1B‐mediated rifampicin interaction studies
por: Yoshikado, Takashi, et al.
Publicado: (2022)

Crystal structures and calorimetry reveal catalytically relevant binding mode of coproporphyrin and coproheme in coproporphyrin ferrochelatase
por: Hofbauer, Stefan, et al.
Publicado: (2019)

Structure of human drug transporters OATP1B1 and OATP1B3
por: Ciută, Anca-Denise, et al.
Publicado: (2023)

In Vitro to In Vivo Extrapolation Linked to Physiologically Based Pharmacokinetic Models for Assessing the Brain Drug Disposition
por: Murata, Yukiko, et al.
Publicado: (2022)

Role of OATP1B1 and OATP1B3 in Drug-Drug Interactions Mediated by Tyrosine Kinase Inhibitors
por: Garrison, Dominique A., et al.
Publicado: (2020)

Classification of Inhibitors of Hepatic Organic Anion Transporting Polypeptides (OATPs): Influence of Protein Expression on Drug–Drug Interactions
por: Karlgren, Maria, et al.
Publicado: (2012)

Regulation of Organic Anion Transporting Polypeptides (OATP) 1B1- and OATP1B3-Mediated Transport: An Updated Review in the Context of OATP-Mediated Drug-Drug Interactions
por: Alam, Khondoker, et al.
Publicado: (2018)

Effect of Cyclosporin A and Impact of Dose Staggering on OATP1B1/1B3 Endogenous Substrates and Drug Probes for Assessing Clinical Drug Interactions
por: Mochizuki, Tatsuki, et al.
Publicado: (2022)

Use of In Vivo Imaging and Physiologically-Based Kinetic Modelling to Predict Hepatic Transporter Mediated Drug–Drug Interactions in Rats
por: Melillo, Nicola, et al.
Publicado: (2023)

Active site architecture of coproporphyrin ferrochelatase with its physiological substrate coproporphyrin III: Propionate interactions and porphyrin core deformation
por: Dali, Andrea, et al.
Publicado: (2023)

A “middle‐out approach” for the prediction of human drug disposition from preclinical data using simplified physiologically based pharmacokinetic (PBPK) models
por: Yau, Estelle, et al.
Publicado: (2023)

Differential Preincubation Effects of Nicardipine on OATP1B1- and OATP1B3-Mediated Transport in the Presence and Absence of Protein: Implications in Assessing OATP1B1- and OATP1B3-Mediated Drug–Drug Interactions
por: Kayesh, Ruhul, et al.
Publicado: (2023)

Molecular Recognition of Imidazole-Based Drug Molecules by Cobalt(III)- and Zinc(II)-Coproporphyrins in Aqueous Media
por: Mamardashvili, Galina, et al.
Publicado: (2023)

Physiologically‐Based Pharmacokinetic Modelling of Creatinine‐Drug Interactions in the Chronic Kidney Disease Population
por: Takita, Hiroyuki, et al.
Publicado: (2020)

Mechanistic Models as Framework for Understanding Biomarker Disposition: Prediction of Creatinine‐Drug Interactions
por: Scotcher, Daniel, et al.
Publicado: (2020)

Results From Drug–Drug Interaction Studies In Vitro and In Vivo Investigating the Inhibitory Effect of Finerenone on the Drug Transporters BCRP, OATP1B1, and OATP1B3
por: Heinig, Roland, et al.
Publicado: (2022)

Influence of the OATP Polymorphism on the Population Pharmacokinetics of Methotrexate in Chinese Patients
por: Wang, Zhiqi, et al.
Publicado: (2019)

Mechanistic in vitro studies indicate that the clinical drug–drug interactions between protease inhibitors and rosuvastatin are driven by inhibition of intestinal BCRP and hepatic OATP1B1 with minimal contribution from OATP1B3, NTCP and OAT3
por: Elsby, Robert, et al.
Publicado: (2023)

Various effects of repeated rifampin dosing on coproporphyrin levels in humans
por: Kinzi, Jonny, et al.
Publicado: (2023)

Investigation of simplified physiologically‐based pharmacokinetic models in rat and human
por: Yau, Estelle, et al.
Publicado: (2023)

Dose‐Dependent Inhibition of OATP1B by Rifampicin in Healthy Volunteers: Comprehensive Evaluation of Candidate Biomarkers and OATP1B Probe Drugs
por: Mori, Daiki, et al.
Publicado: (2020)

Organic anion transporting polypeptides OATP1B1 and OATP1B3 and their genetic variants influence the pharmacokinetics and pharmacodynamics of raloxifene
por: Trdan Lušin, Tina, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_7nrnv8j8cjvnnvmnso024a1huc